Overview

Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence

Status:
NOT_YET_RECRUITING

Trial end date:
2029-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the impact of iparomlimab and tuvonralimab as preoperative neoadjuvant therapy on recurrence-free survival (RFS), along with its potential improvement in overall survival (OS), in patients with resectable hepatocellular carcinoma (HCC) at high risk of recurrence.

Phase:

PHASE2

Details

Lead Sponsor:

Tongji Hospital

Collaborator:

Qilu Pharmaceutical Co., Ltd.